Learn the dominant sequences for the peripheral and transition zones in PI-RADS v2.1, the role of DCE, index-lesion selection, and a practical report example.
Apply the classification or measurement steps from this guide in an interactive tool.
PI-RADS v2.1 is a standardized assessment system that assigns a category from 1 to 5 to reflect the likelihood of clinically significant prostate cancer on multiparametric MRI. The most important rule is: DWI is the dominant sequence in the peripheral zone, whereas T2-weighted imaging is the dominant sequence in the transition zone.
The PI-RADS category is based on MRI findings only. PSA, PSA density, digital rectal examination, family history, and prior biopsy results are not added to the category, although they are considered together when making biopsy and management decisions.
| Category | Likelihood statement for clinically significant cancer |
|---|---|
| PI-RADS 1 | Very low |
| PI-RADS 2 | Low |
| PI-RADS 3 | Intermediate/equivocal |
| PI-RADS 4 | High |
| PI-RADS 5 | Very high |
PI-RADS is not a stand-alone biopsy guideline. The official document emphasizes considering biopsy for PI-RADS 4–5 lesions and using clinical factors to guide decisions for PI-RADS 3 lesions.
Poor technical quality is a major cause of incorrect categorization. Before reporting, check:
If a sequence is technically non-diagnostic, “X” may be assigned for that sequence. When DWI is inadequate—particularly for peripheral-zone assessment—repeat acquisition should be considered when possible.
Zone assignment is fundamental because it determines the dominant sequence.
When a lesion involves more than one zone, assess where its center and predominant component are located. Using the prostate sector map facilitates targeted biopsy and follow-up comparison.
In the peripheral zone, the overall category usually follows the DWI score:
The main scenario in which DCE directly changes the category is a DWI 3 lesion in the PZ. DCE is positive when there is focal early enhancement, or enhancement contemporaneous with adjacent prostatic tissue, corresponding to the suspicious focus. Diffuse enhancement or enhancement that does not match the T2/DWI abnormality is not considered positive.
Distinguishing lesions from benign prostatic hyperplasia is more difficult in the transition zone. T2 appearance is dominant:
In v2.1, DWI can upgrade selected TZ lesions:
DCE is not the sequence that determines the overall category in the TZ.
The largest dimension and invasive behavior are important when distinguishing PI-RADS 4 from 5. In general, a lesion measuring 1.5 cm or more, or definite extraprostatic extension/invasive behavior, supports PI-RADS 5.
Measure the lesion on the sequence and plane that show it best. At minimum, report the largest diameter on the axial image. If extraprostatic extension is suspected, do not stop at the category. Also describe capsular irregularity, neurovascular-bundle involvement, seminal-vesicle invasion, and the relationship to adjacent organs.
PI-RADS v2.1 recommends marking up to four suspicious PI-RADS 3–5 lesions on the sector map. The index lesion is:
This rule highlights that a small lesion extending beyond the capsule may be more important than a larger intraprostatic lesion.
Prostate volume should be reported in every examination. The ellipsoid formula is widely used:
AP diameter × craniocaudal diameter × transverse diameter × 0.52
The volume allows calculation of PSA density. PSA density is not incorporated into the PI-RADS category, but it may be particularly important in the clinical management of PI-RADS 3 lesions.
Findings: A 9 mm lesion in the left posterolateral peripheral zone, focally low on ADC and high on high-b-value DWI, with definite but not marked diffusion restriction. DCE demonstrates corresponding focal early enhancement.
Findings: A 12 mm, mostly encapsulated, homogeneous, mildly hypointense nodule in the right anterior transition zone; DWI score 4.
Prostate volume is 48 mL. In the left posterolateral peripheral zone at the mid gland, corresponding to sector LM-PZpl, there is an 11 mm focal lesion. The lesion is markedly hypointense on the ADC map and markedly hyperintense on high-b-value DWI, with a DWI score of 4. Focal early enhancement is present on DCE. No evidence of extraprostatic extension is identified. The overall PI-RADS v2.1 category is 4.
Impression:
PI-RADS 4 lesion in the left peripheral zone, highly suspicious for clinically significant prostate cancer. Urologic assessment is recommended in conjunction with the clinical findings, PSA density, and biopsy history.
DWI is dominant in the PZ; T2 is dominant in the TZ.
The main categorical effect of DCE is on DWI 3 lesions in the PZ.
Typical, completely encapsulated BPH nodules often do not require separate scoring.
PSA and PSA density affect management, not the MRI category.
A higher category or extraprostatic extension takes priority.
The sector, series/image number, and size may be critical for targeted biopsy.
No. It is the category in which the likelihood of clinically significant cancer is equivocal. PSA density, age, risk history, prior biopsy, and local practice are added to the decision-making process.
Biparametric MRI approaches may be used, but PI-RADS v2.1 includes specific rules regarding technical adequacy and missing sequences. Reporting should follow the institutional protocol and current evidence.
No. The system uses a zone-based dominant sequence and specific upgrade rules.
This content is educational and is not patient-specific medical advice. Every phrase, template, classification result, and recommendation must be verified and adapted by a physician using the complete examination, clinical context, current guidelines, and institutional protocol.
Use the relevant RadPhrases calculator, then verify the result against the official guideline and the complete examination.
